National Alzheimer's Summit

On October 13-14, 2021, join UsAgainstAlzheimer's as we bring together the leading thinkers, advocates and experts across the nation and the world in the effort to end Alzheimer’s disease. The 2021 Summit will explore solutions to the most pressing challenges facing the movement in the drive to effectively treat and prevent the disease.

Say Hello to BrainGuide

Our platform BrainGuide™ empowers people of all ages and communities to understand and take action on brain health and Alzheimer's disease.

UsAgainstAlzheimer's Letter to Secretary Becerra Featured in POLITICO

UsAgainstAlzheimer's letter to Health and Human Services Secretary Becerra was featured in POLITICO Pulse. The letter urged the Secretary to update the National Alzheimer’s Project Act plan with a sixth pillar focused on the prevention of Alzheimer's & related dementias through risk reduction.

New Data Spotlights the Congressional Districts with the Highest Prevalence of Alzheimer’s among Blacks and Latinos

UsAgainstAlzheimer’s Center for Brain Health Equity released a new data brief highlighting the 41 congressional districts with the highest prevalence of Alzheimer’s disease and related dementias (ADRD) among Black Americans and Latinos in the traditional Medicare program. The brief details how government leaders can take action to help these hard-hit communities of color.

New Alzheimer’s Treatment Must Be Affordable and Accessible; with Faster and More Inclusive Phase 4 Confirmatory Trial

UsAgainstAlzheimer’s calls on Biogen, the FDA and insurers to come together to solve four key issues that are critical for patients: affordability, equity, the length and diversity of the Phase 4 confirmatory trial, and who is most likely to benefit from the drug.

UsAgainstAlzheimer’s Hails FDA Approval of Aducanumab, the First Disease-Modifying Therapy for Early-Stage Alzheimer’s

UsAgainstAlzheimer’s issued the following statement from George Vradenburg, chairman and co-founder, on the Food and Drug Administration’s decision to approve Biogen’s aducanumab, the first disease-modifying therapy for early-stage Alzheimer’s.

National Alzheimer's Summit

Say Hello to BrainGuide

UsAgainstAlzheimer's Featured in POLITICO

New Data Spotlights the Congressional Districts with the Highest Prevalence of Alzheimer’s among Blacks and Latinos

New Alzheimer’s Treatment Must Be Affordable and Accessible; with Faster and More Inclusive Phase 4 Confirmatory Trial

UsAgainstAlzheimer’s Hails FDA Approval of Aducanumab, the First Disease-Modifying Therapy for Early-Stage Alzheimer’s

UsAgainstAlzheimer's: Working to End Alzheimer's Disease  

The Alzheimer’s pandemic is one of the most significant health and social economic crises of this generation. It is a national and global emergency that has a devastating health, social and economic toll on millions of people living with this disease, their families and caregivers.

UsAgainstAlzheimer’s exists to conquer Alzheimer’s disease. Since our founding in 2010, we have taken on the toughest problems in the fight to end Alzheimer’s. Our work is driven by the urgency to find effective treatments and the prevention steps needed to reach the time where no one is lost to Alzheimer’s.

We bring all of “Us” together to:

In the past decade, progress has been made, with more hope on the horizon now than ever before.

But every day of delay is another day lost to the millions of people affected by this devastating disease. If nothing changes, by 2050, 14 million Americans will be living with Alzheimer’s at an annual cost of more than $1 trillion. The time to act is now.

Recent News and Blog Posts

  • March 15, 2021

    A Year of Stress, Isolation and Decline: New Survey Spotlights Effects of COVID-19 Pandemic on Alzheimer’s Patients and Caregivers

    A new UsAgainstAlzheimer’s A-LIST® survey shows the coronavirus pandemic and related closures...

    Read more
  • March 13, 2021

    UsAgainstAlzheimer’s Statement on Promising Results for Donanemab in Slowing Decline in Early Alzheimer’s Patients

    UsAgainstAlzheimer’s issued the following statement on the release by Eli Lilly of...

    Read more
  • March 08, 2021

    UsAgainstAlzheimer’s Statement on the Retirement Announcement of Sen. Roy Blunt

    “Roy Blunt is a true champion in the fight to stop Alzheimer’s...

    Read more
  • Greg O'Brien

    A Case for FDA Approval: Biogen’s Aducanumab - First-Ever Drug to Slow Progression of Alzheimer’s

    Time kills deals, as the saying goes. And the biggest deal on...

    Read more
  • February 10, 2021

    UsAgainstAlzheimer’s Calls for $289 Million Increase in FY22 Federal Spending for NIH Alzheimer’s Research

    UsAgainstAlzheimer’s released the following statement on the Alzheimer’s community’s recommended $289 million...

    Read more
  • January 25, 2021

    Partnership Launched to Fight Alzheimer’s Worldwide

    COVID-19 will be the priority for health systems around the world in...

    Read more

Reports

  • Resources

    2020 Annual Report

    In these pages, you will find highlights of the game-changing accomplishments and tremendous progress of UsAgainstAlzheimer's and our partners in the year of 2020. 

  • Resources

    A-LIST Pulse of the Community: Volume 8, June 2021

    The UsAgainstAlzheimer’s A-LIST® is an online community of more than 8,600 people living with Alzheimer’s and other dementias, current and former caregivers, and those concerned about brain health, who have...

  • Resources
    Thumbnail

    Place & Brain Health Equity: Understanding the County-Level Impacts of Alzheimer’s

    The effects of where people live, and the social determinants of health are under-recognized and under-appreciated in our national response to effectively treat and prevent Alzheimer’s. This report found that...